Search

Displaying results 4871 - 4880 of 9670 in total
  1. Drug

    Amubarvimab

    go.drugbank.com/drugs/DB16493
    Investigational

    Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.

  2. Drug

    Clobetasol

    go.drugbank.com/drugs/DB11750
    ApprovedInvestigationalWithdrawn

    Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.

  3. Drug

    Dopexamine

    go.drugbank.com/drugs/DB12313
    ApprovedWithdrawn

    Dopexamine has been used in trials studying the diagnostic and treatment of Free Flap, Oral Cancer, Hypotension, Septic Shock, and Head and Neck Cancer.

  4. Drug

    Theralizumab

    go.drugbank.com/drugs/DB15717
    Investigational

    After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia and human cytokine release).[A216527,A216532]

  5. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    It is being developed by Exelixis, Inc. … XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

  6. Drug

    TAK-428

    go.drugbank.com/drugs/DB05499
    Experimental

    It is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors.

  7. Drug

    Vilzemetkib

    go.drugbank.com/drugs/DB21704
    Experimental

    Vilzemetkib has a monoisotopic molecular weight of 642.27 Da. … The usage of the INN stem '-metkib' in the name indicates that Vilzemetkib is a MET (mesenchymal epithelial transition factor) kinase inhibitor.

  8. Drug

    Propentofylline

    go.drugbank.com/drugs/DB06479
    Experimental

  9. Drug

    Abexinostat

    go.drugbank.com/drugs/DB12565
    Investigational

    Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. … It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.

  10. Drug

    Spaglumic acid

    go.drugbank.com/drugs/DB08835
    Investigational

    Thus it is used in allergic conditions such as allergic conjunctivitis.